整合实用性与实施科学随机临床试验方法:PRECIS-2分析
该研究使用PRECIS-2及PRECIS-2-PS工具评估两项多中心随机临床试验的设计,七名评分者接受培训后编码,计算组内相关系数和Kappa统计量,并采用RAPICE定性方法分析整合主题。结果显示两个试验的PRECIS-2轮均更偏实用性而非解释性,复合评分均值和中位数≥4,主要意向性治疗分析域评分最实用(均值=5.0,SD=0),随访/数据收集域最偏解释性(均值范围3.14-3.43,SD范围0.49-0.69)。
要点
- PRECIS-2与PRECIS-2-PS可同时用于可行且可靠地表征以患者和提供者为目标的临床试验。
- 两个试验的所有PRECIS-2轮均评为更偏实用性而非解释性,复合评分均值和中位数≥4。
- 主要意向性治疗分析域评分最实用(均值=5.0,SD=0),随访/数据收集域最偏解释性(均值范围3.14-3.43,SD范围0.49-0.69)。
核心结论
- PRECIS-2和PRECIS-2-PS可同时使用,可行且可靠地表征以患者和提供者为目标的临床试验。
- 整合实用性与实施科学临床试验方法可通过使用PRECIS-2和PRECIS-2-PS等通用指标推进。
- 未来研究可聚焦于临床试验政策研究方法开发。
研究设计与样本
- 使用PRECIS-2和PRECIS-2-PS工具评估两项多中心随机临床试验的设计,试验针对患者层面有效性结局、提供者层面实践改变和卫生保健系统政策。
- 七名评分者接受PRECIS-2培训后应用工具对两项试验进行编码。
- 采用RAPICE定性方法理解从PRECIS-2评分和终期政策峰会中得出的整合主题。
- 试验注册:DO-SBIS ClinicalTrials.gov NCT00607620,注册于2008年1月29日;TSOS ClinicalTrials.gov NCT02655354,注册于2015年7月27日。
主要发现
- 患者和提供者聚焦的PRECIS-2域复合评分的ICC范围为0.77至0.87,Kappa值范围为0.25至0.37,反映两项试验总体 fair-to-good 的评分者间一致性。
- 所有四个PRECIS-2轮均评为更偏实用性而非解释性,复合评分均值和中位数≥4。
- 跨试验,主要意向性治疗分析域一致评为最实用(均值=5.0,SD=0),随访/数据收集域评为最偏解释性(均值范围=3.14-3.43,SD范围=0.49-0.69)。
- RAPICE现场笔记识别出与PRECIS-2培训改进相关的主题,以及与使用试验数据 informing 美国创伤护理系统实践改变相关的政策主题;政策主题未被PRECIS-2评分捕获。
关键数值与推荐
- ICC范围0.77-0.87,Kappa范围0.25-0.37,反映两项试验总体 fair-to-good 评分者间一致性。
- 所有PRECIS-2轮复合评分均值和中位数≥4,评为更偏实用性而非解释性。
- 主要意向性治疗分析域均值=5.0,SD=0;随访/数据收集域均值范围3.14-3.43,SD范围0.49-0.69。
临床怎么用
- PRECIS-2和PRECIS-2-PS可同时使用,可行且可靠地表征以患者和提供者为目标的临床试验。
- 整合实用性与实施科学临床试验方法可通过使用PRECIS-2和PRECIS-2-PS等通用指标推进。
- 未来研究可聚焦于临床试验政策研究方法开发。
局限性
- 未来研究可聚焦于临床试验政策研究方法开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over the past two decades, pragmatic and implementation science clinical trial research methods have advanced substantially. Pragmatic and implementation studies have natural areas of overlap, particularly relating to the goal of using clinical trial data to leverage health care system policy changes. Few investigations have addressed pragmatic and implementation science randomized trial methods development while also considering policy impact. METHODS: The investigation used the PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) and PRECIS-2-Provider Strategies (PRECIS-2-PS) tools to evaluate the design of two multisite randomized clinical trials that targeted patient-level effectiveness outcomes, provider-level practice changes and health care system policy. Seven raters received PRECIS-2 training and applied the tools in the coding of the two trials. Descriptive statistics were produced for both trials, and PRECIS-2 wheel diagrams were constructed. Interrater agreement was assessed with the Intraclass Correlation (ICC) and Kappa statistics. The Rapid Assessment Procedure Informed Clinical Ethnography (RAPICE) qualitative approach was applied to understanding integrative themes derived from the PRECIS-2 ratings and an end-of-study policy summit. RESULTS: The ICCs for the composite ratings across the patient and provider-focused PRECIS-2 domains ranged from 0.77 to 0.87, and the Kappa values ranged from 0.25 to 0.37, reflecting overall fair-to-good interrater agreement for both trials. All four PRECIS-2 wheels were rated more pragmatic than explanatory, with composite mean and median scores ≥ 4. Across trials, the primary intent-to-treat analysis domain was consistently rated most pragmatic (mean = 5.0, SD = 0), while the follow-up/data collection domain was rated most explanatory (mean range = 3.14-3.43, SD range = 0.49-0.69). RAPICE field notes identified themes related to potential PRECIS-2 training improvements, as well as policy themes related to using trial data to inform US trauma care system practice change; the policy themes were not captured by the PRECIS-2 ratings. CONCLUSIONS: The investigation documents that the PRECIS-2 and PRECIS-2-PS can be simultaneously used to feasibly and reliably characterize clinical trials with patient and provider-level targets. The integration of pragmatic and implementation science clinical trial research methods can be furthered by using common metrics such as the PRECIS-2 and PRECIS-2-PS. Future study could focus on clinical trial policy research methods development. TRIAL REGISTRATION: DO-SBIS ClinicalTrials.gov NCT00607620. registered on January 29, 2008. TSOS ClinicalTrials.gov NCT02655354, registered on July 27, 2015.
引用
- Zatzick D, Palinkas L, Chambers DA, et al. Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis. Trials. 2023. PMID: 37085877. doi:10.1186/s13063-023-07313-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。